SMTI
BuyPremium GrowerFLAGSanara MedTech Inc. · Healthcare · United States · $318M · Avg Vol: $10M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
Insufficient evidence for a screen-pass. Sanara MedTech Inc.: fails the quant gate on value (Q59/V25/M76; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT SANARA MEDTECH INC.
Read
Sanara MedTech Inc. develops and commercializes advanced wound care and surgical tissue repair products, including biologics and sophisticated wound care solutions. The company offers a proprietary product portfolio rooted in regenerative medicine, supported by clinical evidence for efficacy and a specialized sales force. Sanara MedTech is a niche player in the growing wound care market, focusing on innovative solutions for complex medical cases.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.1M | 45.8M | 65.0M | 86.7M | 103.1M | 43.8% | 109.8M | 116.6M | 133.2M | 13.6% |
| EPS | -1.08 | -1.00 | -0.52 | -1.14 | -4.36 | — | — | — | — | — |
| Shares | 7.7M | 8.3M | 8.5M | 8.8M | 8.9M | +16.5% | 9.2M | — | — | — |
| Debt | 0.4M | 0.8M | 11.8M | 32.3M | 48.2M | 226.2% | 48.5M | — | — | — |
| Equity | 30.6M | 41.8M | 44.8M | 39.4M | 5.9M | -33.6% | — | — | — | — |
| Op CF | -4.8M | -5.6M | -3.2M | -23.8K | 6.8M | — | 5.7M | — | — | — |
| Inv CF | -5.3M | -3.5M | -10.2M | -6.6M | -15.0M | — | — | — | — | — |
| Fin CF | 28.3M | -0.6M | 9.6M | 17.4M | 8.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SMTI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SMTI | Sanara MedTech Inc.(you) | $318M | 68 | Buy |
| EMBC | Embecta Corp. | $286M | 88 | Strong Buy |
| ANGO | AngioDynamics, Inc. | $655M | 52 | Hold |
| UTMD | Utah Medical Products, Inc. | $232M | 94 | Strong Buy |
| STAA | STAAR Surgical Company | $1.1B | 57 | Hold |
| PDEX | Pro-Dex, Inc. | $200M | 95 | Strong Buy |
| OSUR | OraSure Technologies, Inc. | $248M | 33 | Sell |
| ATRC | AtriCure, Inc. | $2.5B | 64 | Hold |
| XRAY | DENTSPLY SIRONA Inc. | $2.2B | 58 | Hold |
| LMAT | LeMaitre Vascular, Inc. | $1.8B | 53 | Hold |
Peer medians: ROE -31.0% · P/E 25.1x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.